<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05014815</url>
  </required_header>
  <id_info>
    <org_study_id>AdvanTIG-205</org_study_id>
    <secondary_id>2021-001075-17</secondary_id>
    <nct_id>NCT05014815</nct_id>
  </id_info>
  <brief_title>Ociperlimab With Tislelizumab and Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind Study of Ociperlimab (BGB A1217) and Tislelizumab With Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Without Sensitizing EGFR or ALK Mutations Who Have Received No Previous Treatment for Metastatic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of ociperlimab with tislelizumab and&#xD;
      chemotherapy compared with treatment with tislelizumab and chemotherapy in participants with&#xD;
      metastatic non-small cell lung cancer (NSCLC)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) as Assessed by Investigators</measure>
    <time_frame>Up to approximately 30 months</time_frame>
    <description>PFS will be defined as the time from the date of randomization to the date of the first objectively documented tumor progression per RECIST v1.1, or death, whichever occurs first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) as Assessed by Investigators</measure>
    <time_frame>Up to approximately 30 months</time_frame>
    <description>ORR will be defined as the proportion of participants with a documented, confirmed complete response or partial response per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 30 months</time_frame>
    <description>OS will be defined as the time from the date of randomization to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Adverse Events (AEs)</measure>
    <time_frame>90 days (±14) after last dose</time_frame>
    <description>The incidence and severity of AEs will be determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of ociperlimab and tislelizumab at prespecified timepoints</measure>
    <time_frame>Up to approximately 12 months or end of treatment visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenic responses to ociperlimab and tislelizumab, evaluated through detection of anti-drug antibodies (ADAs).</measure>
    <time_frame>Up to approximately 12 months or end of treatment visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Ociperlimab + tislelizumab histology-based chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Placebo + tislelizumab + histology-based chemotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>Tislelizumab intravenous injection</description>
    <arm_group_label>Arm A: Ociperlimab + tislelizumab histology-based chemotherapy</arm_group_label>
    <arm_group_label>Arm B: Placebo + tislelizumab + histology-based chemotherapy</arm_group_label>
    <other_name>BGB-A317</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ociperlimab</intervention_name>
    <description>Ociperlimab intravenous injection</description>
    <arm_group_label>Arm A: Ociperlimab + tislelizumab histology-based chemotherapy</arm_group_label>
    <other_name>BGB-A1217</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>histology-based chemotherapy</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>Arm A: Ociperlimab + tislelizumab histology-based chemotherapy</arm_group_label>
    <arm_group_label>Arm B: Placebo + tislelizumab + histology-based chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as an intravenous injection</description>
    <arm_group_label>Arm B: Placebo + tislelizumab + histology-based chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed metastatic (Stage IV) squamous or non-squamous NSCLC.&#xD;
&#xD;
          2. Treatment-naive for metastatic squamous or non-squamous NSCLC.&#xD;
&#xD;
          3. Agreement to provide archival tissue or fresh biopsy for the prospectively&#xD;
             determination of PD-L1 levels and retrospective analysis of other biomarkers.&#xD;
&#xD;
          4. At least 1 measurable lesion as defined per RECIST v1.1.&#xD;
&#xD;
             .&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with NSCLC that harbors an EGFR-sensitizing mutation or ALK gene&#xD;
             translocation.&#xD;
&#xD;
          2. Prior therapy with an anti-programmed cell death protein (PD-1), anti-PD-L1,&#xD;
             anti-programmed cell death ligand-2 (PD-L2), anti-TIGIT, or any other antibody or drug&#xD;
             specifically targeting T-cell costimulation or checkpoint pathways.&#xD;
&#xD;
          3. Active leptomeningeal disease or uncontrolled, untreated brain metastasis.&#xD;
&#xD;
          4. Any active malignancy ≤ 2 years before randomization except for the specific cancer&#xD;
             under investigation in this study and any locally recurring cancer that has been&#xD;
             treated curatively (for example, resected basal or squamous cell skin cancer,&#xD;
             superficial bladder cancer, carcinoma in situ of the cervix or breast).&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>1-877-828-5568</phone>
    <email>ClinicalTrails@beigene.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Non-Squamous</keyword>
  <keyword>Ociperlimab</keyword>
  <keyword>Tislelizumab</keyword>
  <keyword>Anti-PD-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

